Advantages of Fluorescent Probes in GPCR Assays
The field of drug discovery faces a critical challenge: despite their vast therapeutic potential, many G Protein-Coupled Receptors (GPCRs) remain unexplored. These receptors play a fundamental role in numerous physiological processes and are the target of 35% of FDA-approved drugs. However, more than half of non-sensory GPCRs have yet to be clinically leveraged, opening the door to groundbreaking treatments for various diseases.
One promising approach to closing this gap is the use of fluorescent probes in GPCR screening assays. Thanks to their numerous advantages, fluorescent probes offer a compelling alternative to radioligands in GPCR assays.
What Are the Advantages of Fluorescent Probes in GPCR Assays?
Fluorescent ligands, ligands with the desired affinity or functional activity for the target of interest conjugated to fluorescent dyes through linkers, are effective in GPCR research. They enable receptor localization, internalization tracking, and safer alternatives to GPCR radioligand binding assays. Beyond GPCR screening assays, they provide insights into receptor activation dynamics, ligand binding geometry, and receptor interactions, significantly advancing pharmacological and structural studies.
Traditional GPCR assays have relied on radiolabeled ligands, but these methods come with several limitations, including safety concerns, low temporal resolution, and the need for specialized disposal procedures. In contrast, fluorescent probes have revolutionized the field by offering a safer, more versatile, and higher-resolution approach to studying receptor-ligand interactions.
One of the major advantages of using fluorescent probes in GPCR screening assays is their ability to provide real-time data on receptor activation, ligand binding, and downstream signaling using live-imaging modalities. Unlike radioligands, which produce mainly endpoint measurements, fluorescent ligands enable dynamic observation of receptor states.
A notable example is shown in Figure 1A. A hA2B/hA3 adenosine receptor fluorescent antagonist (CELT-327) was added to a colon cancer cell line (HCT116) and a detectable fluorescence signal appeared only 1 minute after the addition. It became evident and membrane-specific at minute 2 and increased exponentially until saturation plateau after approximately 10 minutes. Fluorescent ligands show rapid diffusion and homogeneous distribution within cell monolayers, staining both apicobasal and lateral membranes (Figure 1B).
Figure 1. Real-time dynamic labeling of A2BAR. A) Representative confocal images of HCT116 cells pre-stained with CellTracker Green (lower panels) and labeled in real-time with CELT-327 250 nM, added at timepoint 0 (upper panels). Scale bars: 50 μm. B) Orthogonal projections on a selected area of images in A. Scale bar: 20 μm. C) Quantification of CELT-327 average fluorescence intensity over time.
Another critical advantage of fluorescent ligands is their superior safety and environmental profile. Unlike radiolabeled compounds, fluorescent probes do not pose radiation hazards, making them easier to handle and store. This also eliminates the need for costly and complex radioactive waste disposal and permits, streamlining experimental workflows and avoiding experiment outsourcing.
Fluorescent ligands also offer enhanced sensitivity and specificity. By leveraging advanced imaging techniques such as Fluorescence Resonance Energy Transfer (FRET) and Fluorescence Polarization (FP), researchers can monitor receptor activity with high spatial and temporal resolution.
What Are the Challenges of Fluorescent Probes?
Despite their numerous advantages, fluorescent ligands face some challenges.
One of the most significant drawbacks is photobleaching, where prolonged exposure to excitation light causes the fluorescent signal to diminish over time. This can affect long-term imaging studies and necessitates the use of stable fluorophores or specialized imaging techniques to mitigate signal loss. Advances in the field have enabled the development of linkers and dyes that offer higher chemical and photostability to maintain longer signal integrity.
Another issue is spectral overlap, which can create background noise and interfere with multi-color experiments. Using fluorescent dyes that emit at longer wavelengths, such as infrared, widens the measurement spectra, allows multicolor experiments, and enables fluorescence imaging in vivo. Moreover, advanced imaging modalities, such as confocal microscopy, help separate overlapping signals.
Celtarys fluorescent ligands show no background even without washing before cell visualization, as demonstrated in Figure 2. Our portfolio includes fluorescent ligands conjugated to near-infrared fluorophores (CELT-075 hD2 dopamine receptor fluorescent antagonist and CELT-095 hM1/M2 muscarinic receptor fluorescent antagonist). But not only that, thanks to our proprietary conjugation technology, we can generate hundreds of different combinations of pharmacophore and linker architecture, including specific fluorophores for multi-color experiments.
Non-specific binding has been another challenge, as fluorescent ligands may bind to unintended cellular components, leading to misleading results. Nevertheless, new rational, convergent, and efficient synthetic strategies allow the production of highly specific fluorescent ligands. When used in a live co-culture of colon cancer cells and human primary cancer-associated fibroblasts, our hA2B/hA3 adenosine receptor fluorescent antagonist (CELT-327) shows a specific membrane fluorescent labeling in HCT116 cells (Figure 2).
Figure 2. Representative confocal images of co-cultures of HCT116 cells and human primary CAFs. The dashed line represents the frontier between both cell types. CAFs are labeled with CellTracker (Green), and cocultures are labeled with CELT-327 250 nM. Scale bar 100 μm.
Fluorescent Probes in GPCR Assays: Protocol
Most of the protocols employing fluorescent probes in GPCR assays begin with the preparation of the cellular system. Cells expressing the receptor of interest are cultured under conditions that preserve their physiological characteristics. Some protocols that do not involve real-time receptor dynamics, internalization, and live-cell imaging, can also use cell fragments, such as membrane preparations or receptor-expressing sections attached to a culture plate.
Briefly, once the cells are ready, they are incubated with the appropriate fluorescent ligand. For visualization purposes, cells can be co-stained with a green live-cell dye (Calcein) or Hoechst. For fixed cell preparations, DAPI (4′,6-diamidino-2-phenylindole), a DNA-specific fluorescent probe, can be used.After incubation, cells are observed using a confocal microscope.
In competition binding assays, a competing ligand is introduced to displace the fluorescent ligand, leading to a measurable decrease in fluorescence signal that is recorded over time using high-content analysis systems.
Celtarys’ protocol section includes detailed protocols for diverse applications and fluorescent ligands.
Contact us if you have any questions about our fluorescent ligands. Our scientific team can guide you choose or design the right fluorescent ligand for your research.
References
Barbazán J, Majellaro M, Martínez AL, Brea JM, Sotelo E, Abal M. Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR ligands. Biomed Pharmacother. 2022 Sep;153:113408. doi: 10.1016/j.biopha.2022.113408.
Casadó V, Casadó-Anguera V. What are the current trends in G protein-coupled receptor targeted drug discovery? Expert Opin Drug Discov. 2023 Jul-Dec;18(8):815-820. doi: 10.1080/17460441.2023.2216014.
Ciruela F, Jacobson KA, Fernández-Dueñas V. Portraying G protein-coupled receptors with fluorescent ligands. ACS Chem Biol. 2014 Sep 19;9(9):1918-28. doi: 10.1021/cb5004042.
Soave M, Briddon SJ, Hill SJ, Stoddart LA. Fluorescent ligands: Bringing light to emerging GPCR paradigms. Br J Pharmacol. 2020 Mar;177(5):978-991. doi: 10.1111/bph.14953.
Sridharan R, Zuber J, Connelly SM, Mathew E, Dumont ME. Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors. Biochim Biophys Acta. 2014 Jan;1838(1 Pt A):15-33. doi: 10.1016/j.bbamem.2013.09.005.
